A Direct Comparison of the Natriuretic Peptides and Their Relationship to Survival in Chronic Heart Failure of a Presumed Non-Ischaemic Origin
Authors:
- Eric StantonESEric Stanton
- Hairinda C WijeysunderaHWHairinda C Wijeysundera
- PRAISE-2 study investigatorsPIPRAISE-2 study investigators
- 28 May 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 7 (4) , 557-565
Abstract
The natriuretic peptides have been validated as sensitive and specific markers of left ventricular dysfunction; brain natriuretic peptide (BNP), N-terminal atrial natriuretic peptide (NT-proANP) and N-terminal brain natriuretic peptide (NT-proBNP) elevations have been associated with New York Heart Association (NYHA) Class I–IV heart failure. We directly compared the association of each of these markers with 1-year survival in 173 patients with chronic heart failure of a presumed nonischaemic origin entering the PRAISE-2 Trial, a clinical study which assessed the therapeutic effect of Amlodipine in patients with NYHA Class III and IV heart failure and a left ventricular ejection fraction (LVEF) <30%. BNP, NT-proBNP, and NT-proANP levels were all correlated with 1-year mortality by univariate Cox proportional hazards analyses. With respect to multivariate Cox proportional hazards regression models containing variables deemed significant in univariate analyses, NT-proANP alone was identified as an independent predictor of 1-year mortality when log-transformed continuous covariates were utilized in the analysis. When the analysis was repeated using dichotomous covariates, NT-proANP remained the most significant predictor of 1-year mortality, followed by NT-proBNP, NYHA classification and BNP. We conclude that all three natriuretic peptides are significant predictors of short-term mortality in subjects with chronic congestive heart failure (CHF) of a presumed nonischaemic origin. Larger prospective studies are required to validate the clinical utility of NT-proANP as a discriminating marker of short-term survival, and to validate proposed cutoffs of approximately 2300 pmol/l for NT-proANP, 1500 pg/ml for NT-proBNP, and 50 pmol/l for BNP as prognostic indicators of adverse short-term outcome.Keywords
This publication has 35 references indexed in Scilit:
- New technologies and potential cost savings related to morbidity and mortality reduction in Class III/IV heart failure patients in CanadaInternational Journal of Cardiology, 2003
- N-Terminal Pro-B–Type Natriuretic Peptide and Long-Term Mortality in Acute Coronary SyndromesCirculation, 2002
- Rapid Measurement of B-Type Natriuretic Peptide in the Emergency Diagnosis of Heart FailureNew England Journal of Medicine, 2002
- Plasma N-terminal pro-BNP predicts the occurrence of major clinical events in severe chronic heart failure: results of a substudy of the COPERNICUS trialJACC, 2002
- Heart failure and neuroendocrine activation: diagnostic, prognostic and therapeutic perspectivesClinical Physiology and Functional Imaging, 2001
- The Prognostic Value of B-Type Natriuretic Peptide in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2001
- Plasma A- and B-type natriuretic peptides: physiology, methodology and clinical useCardiovascular Research, 2001
- Measurement and importance of plasma brain natriuretic peptide and related peptidesAnnals of Clinical Biochemistry: International Journal of Laboratory Medicine, 2001
- Survival after the onset of congestive heart failure in Framingham Heart Study subjects.Circulation, 1993
- A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in ratsLife Sciences, 1981